Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

August 1, 2020

Study Completion Date

December 1, 2020

Conditions
Refractory Acute Myelogenous LeukemiaRelapsed Acute Myelogenous Leukemia
Interventions
BIOLOGICAL

FATE-NK100

"Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."

Trial Locations (1)

55455

University of Minnesota, Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03081780 - Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML | Biotech Hunter | Biotech Hunter